Effect of lifestyle modification and Metformin on Fetuin-A in metabolic syndrome

<p>Dharma Lindarto</p>

Effect of lifestyle modification and Metformin on Fetuin-A in metabolic syndrome

Dharma Lindarto

General Hospital H Adam Malik, Indonesia

:

Abstract

Objective: To evaluate the effects of lifestyle modification and Metformin on Fetuin-A in Metabolic Syndrome (MetS) as defined in 2006 by the International Diabetes Federation (IDF). Methodology: 40 MetS subjects were randomly assigned to treatment with Placebo (n=20) or Metformin (n=20) in addition to lifestyle modification for 12 weeks. Results: All 40 participants completed the study. After 12 weeks, both groups had significant reductions in weight (p<0.001), body mass index (BMI) (p<0.001), waist circumference (WC) (p<0.001), systolic blood pressure (SBP) (p<0.001) and diastolic blood pressure (DBP) (p<0.001). The Placebo group also had significant improvement in fasting plasma glucose (FPG) (p<0.001) and C-reactive protein (CRP) (<0.05). Weight, BMI, WC, FPG, 2-hour postprandial glucose (2h-PPG), high density lipoprotein cholesterol (HDL-C), triglycerides (TG) and Fetuin-A in the Metformin group are decreased significantly compared to the Placebo group. Reduction of plasma Fetuin-A was significantly associated with TG in the Metformin group. Conclusion: Lifestyle modification and treatment with Metformin for 12 weeks improved cardio-metabolic risk factors in MetS and reduced Fetuin-A levels. Further investigations are required to confirm the effects of lifestyle modification and Metformin after an extended follow-up period.